| Literature DB >> 27528862 |
Ravi C Dwivedi1, Mario Navarrete1, Nora Choi2, Victor Spicer1, Claudio Rigatto3, Rakesh C Arora4, Oleg Krokhin1, Julie Ho5, John A Wilkins1.
Abstract
BACKGROUND: The urinary proteome of patients undergoing cardiopulmonary bypass (CPB) may provide important insights into systemic and renal changes associated with the procedure. Such information may ultimately provide a basis to differentiate changes or properties associated with the development of acute kidney injury. While mass spectrometry (MS) analysis offers the potential for in-depth compositional analysis it is often limited in coverage and relative quantitation capacity. The aim of this study was to develop a process flow for the preparation and comparison of the intraoperative urinary proteome.Entities:
Keywords: Cardiac surgery; Data dependent acquisition (DDA); Data independent acquisition (DIA); Information dependent data acquisition (IDA); Label free quantitation; Molecular weight cut off (MWCO) filters; Proteomics; Renal; SWATH; Urine
Year: 2016 PMID: 27528862 PMCID: PMC4983784 DOI: 10.1186/s12014-016-9118-9
Source DB: PubMed Journal: Clin Proteomics ISSN: 1542-6416 Impact factor: 3.988
Baseline patient characteristics
| Variable | Patients (n = 5) |
|---|---|
| Age (years) | 75 (73–77) |
| Male | 3 (60 %) |
| eGFR (mL/min/1.72 m2) | 72.5 (69.2–76.5) |
| Baseline creatinine (mg/dL) | 94 (69–97) |
| THAKAR Score | 2 (1–2) |
| Diabetes mellitus | 1 (20 %) |
| Chronic obstructive pulmonary disease | 1 (20 %) |
| Hospitalized congestive heart failure | 1 (20 %) |
| Previous myocardial infarction | 2 (40 %) |
| Previous CABG | 0 (0 %) |
| Peripheral arterial disease | 1 (20 %) |
| Amputation or peripheral arterial disease bypass | 0 (0 %) |
| Previous cerebrovascular accident | 0 (0 %) |
| Previous transient ischemic attack | 1 (20 %) |
| Type of surgery (isolated CABG) | 3 (60 %) |
| Pump time (min) | 68 (64–95) |
| Cross-clamp time (min) | 54 (36–78) |
| Operating room duration (min) | 254 (250–305) |
| European system for cardiac operation risk evaluation EuroSCORE II | 1.5 % (1.0–2.4 %) |
| Intraoperative urine output (mL) | 1180 (800–1350) |
Values expressed as median (interquartile range) or N (percent). Continuous variables compared using Mann–Whitney test, categorical variables compared using Chi-square or Fisher’s Exact Test
Fig. 1a The chromatographic properties of CPB urine samples processed using 3, 10 or 30 kDa MWCO filters in the modified-FASP method. The total ion chromatogram of each sample is given. Note the peak spreading and altered retention times in the 3 and 10 kDa MWCO membrane processed samples. b The predicted molecular weight and pI distribution of proteins identified from the same urine sample FASP processed with 3, 10 or 30 kDa molecular weight cut-off membranes. The values beside each panel indicate the number of proteins with molecular weights less than 30 kDa and the total number of proteins identified in sample
Fig. 2The use of protein level intensity correlations between 2D DDA/IDA and SWATH runs to improve quantitation reliability. Comparison of log2 protein intensities a START of CPB b 1-hour CPB. c The expression of differences between SWATH and DDA/IDA readouts (at the same time point) as normalized Z-scores identifies proteins that show discordance between the two methods. This provides a basis for discarding the proteins with |Z| > 1.65 in either population (as shown by the red dots), the resulting 475 common proteins (86 % of the 552 protein initial list; the blue dots). This improved the cross-technology difference correlation to R2 = 0.549. d The correlation of difference values for the 77 proteins rejected by this filtering step, shown is very low (R2 = 0.01)
Correlation filtered 2D DDA/IDA and SWATH protein differences of magnitude greater than 1.59 (threefold up regulating at CPB-1-hour) from both methods marked in (A) and less than −1.59 (threefold down regulating at CPB-1-hour) marked in (B)
| SWATH | DDA/IDA | UNIPROT entry | Description |
|---|---|---|---|
| ( | |||
| 2.53 | 3.09 | P01023 | Alpha-2-macroglobulin |
| 1.78 | 3.53 | P04083 | Annexin A1 |
| 2.05 | 3.04 | P04003 | C4b-binding protein alpha chain |
| 3.53 | 5.73 | P00915 | Carbonic anhydrase 1 |
| 1.82 | 4.47 | P49913 | Cathelicidin antimicrobial peptide |
| 1.87 | 2.36 | P36222 | Chitinase-3-like protein 1 |
| 3.47 | 4.00 | P08123 | Collagen alpha-2(I) chain |
| 1.84 | 2.82 | P09871 | Complement C1 s subcomponent |
| 1.86 | 2.01 | P02671 | Fibrinogen alpha chain |
| 2.37 | 2.03 | P02675 | Fibrinogen beta chain |
| 1.76 | 4.09 | P30043 | Flavin reductase (NADPH) |
| 1.64 | 1.84 | P00738 | Haptoglobin |
| 2.1 | 1.79 | P01860 | Ig gamma-3 chain C region |
| 2.09 | 1.99 | P13645 | Keratin, type I cytoskeletal 10 |
| 2.3 | 4.12 | P02533 | Keratin, type I cytoskeletal 14 |
| 3.48 | 6.95 | P08779 | Keratin, type I cytoskeletal 16 |
| 5.44 | 5.87 | Q04695 | Keratin, type I cytoskeletal 17 |
| 2.17 | 4.22 | P13647 | Keratin, type II cytoskeletal 5 |
| 2.09 | 2.79 | P02788 | Lactotransferrin |
| 3.18 | 5.10 | P14780 | Matrix metalloproteinase-9 |
| 2.22 | 2.94 | P05164 | Myeloperoxidase |
| 2.48 | 3.59 | P05109 | Protein S100-A8 |
| ( | |||
| −1.82 | −1.94 | P02763 | Alpha-1-acid glycoprotein 1 |
| −2.35 | −2.10 | P05090 | Apolipoprotein D |
| −2.14 | −3.50 | P55287 | Cadherin-11 |
| −2.23 | −2.87 | P19022 | Cadherin-2 |
| −1.64 | −1.80 | P49747 | Cartilage oligomeric matrix protein |
| −2.39 | −2.86 | P39059 | Collagen alpha-1(XV) chain |
| −1.66 | −2.32 | P08174 | Complement decay-accelerating factor |
| −1.64 | −2.43 | Q9HCU0 | Endosialin |
| −1.92 | −2.97 | P17900 | Ganglioside GM2 activator |
| −3.02 | −2.24 | Q96RW7 | Hemicentin-1 |
| −2.31 | −2.30 | O75144 | ICOS ligand |
| −2.31 | −2.63 | Q9BRK3 | Matrix-remodeling-associated protein 8 |
| −1.72 | −2.20 | P08571 | Monocyte differentiation antigen CD14 |
| −1.78 | −1.62 | Q9BXP8 | Pappalysin-2 |
| −2.63 | −1.72 | P0DJD8 | Pepsin A-3 |
| −2.16 | −1.72 | Q6UXB8 | Peptidase inhibitor 16 |
| −1.7 | −2.24 | Q9HCN6 | Platelet glycoprotein VI |
| −1.92 | −1.60 | P07602 | Prosaposin |
| −1.88 | −2.83 | Q8WZ75 | Roundabout homolog 4 |
| −1.79 | −2.70 | O00241 | Signal-regulatory protein beta-1 |
| −2.02 | −3.47 | P19320 | Vascular cell adhesion protein 1 |
| −2.16 | −2.73 | Q6EMK4 | Vasorin |
| −1.79 | −2.34 | Q12907 | Vesicular integral-membrane protein VIP36 |
| −2.33 | −2.58 | Q96DA0 | Zymogen granule protein 16 homolog B |
These formed the basis for our biological analysis
GO cellular components enriched in differentially regulated proteins
| Term | Up regulated | Down regulated | ||
|---|---|---|---|---|
| Genes |
| Genes |
| |
| Extracellular exosome | 20 | 4.41 × 10−14 | 23 | 4.99 × 10−18 |
| Extracellular membrane-bounded organelle | 20 | 4.41 × 10−14 | 23 | 4.99 × 10−18 |
| Extracellular organelle | 20 | 4.79 × 10−14 | 23 | 5.50 × 10−18 |
| Extracellular region part | 21 | 9.89 × 10−14 | 22 | 3.22 × 10−13 |
| Membrane-bounded vesicle | 20 | 2.81 × 10−12 | 23 | 6.18 × 10−16 |
| Extracellular region | 21 | 3.59 × 10−12 | 22 | 1.33 × 10−11 |
| Vesicle | 20 | 5.11 × 10−12 | 23 | 1.24 × 10−15 |
| Extracellular space | 15 | 1.82 × 10−11 | 11 | 2.95 × 10−5 |
| Blood microparticle | 6 | 1.40 × 10−6 | * | * |
| Cytoplasmic membrane-bounded vesicle lumen | 5 | 3.08 × 10−5 | * | * |
| Vesicle lumen | 5 | 3.27E × 10−5 | * | * |
Only cellular components enriched with a p value of 10−5 or less are reported. Analysis was performed using String database [37]
GO processes enriched in upregulated proteins
| GO term | Humoral immune response | Immune system process | Antibacterial humoral response | Protein activation cascade | Antimicrobial humoral response | Defense response to other organism | Response to inorganic substance | Defense response to bacterium |
|---|---|---|---|---|---|---|---|---|
| Genes | 6 | 12 | 4 | 5 | 4 | 7 | 8 | 6 |
|
| 1.87 × 10−5 | 5.08 × 10−5 | 1.87 × 10−5 | 1.87 × 10−5 | 1.98 × 10−5 | 5.08 × 10−5 | 1.87 × 10−5 | 5.08 × 10−5 |
| ANXA1 | X | X | ||||||
| A2 M | X | |||||||
| C1S | X | X | X | |||||
| C4BPA | X | X | X | |||||
| CAMP | X | X | X | X | X | X | ||
| COL1A2 | X | |||||||
| FGA | X | X | X | X | X | X | X | X |
| FGB | X | X | X | X | X | X | X | X |
| HP | X | X | X | X | ||||
| LTF | X | X | X | X | X | X | ||
| KRT10 | X | |||||||
| KRT14 | X | |||||||
| KRT16 | X | |||||||
| MPO | X | X | X | |||||
| S100A8 | X | X | X | X |
Note only those terms with Bonferroni corrected p values of 10−5 or lower are listed. The proteins assigned to the process are indicated. Analysis was performed using String database [37]